Allergan: ISU urology meeting sponsorship at 5-star Belfast venue raised ‘overall impression’ concerns (AUTH/2547/11/12)

📅 2012 | 🖉 Dr Anzal Qurbain
📊

Key facts

Case numberAUTH/2547/11/12
ComplainantAnonymous group of NHS health professionals (non-contactable)
CompanyAllergan Ltd
IssueSponsorship of a third-party meeting; concerns about excessive hospitality/overall impression (luxury venue, golf, gala dinner referenced in programme)
MeetingIrish Society of Urology (ISU) annual meeting
Location / dateCulloden Estate and Spa, Holywood, Belfast (Northern Ireland), September 2012
Support provided by AllerganEducational grant €1,850 for venue hire and AV costs (no exhibition stand)
Scientific content noted by Panel~1.5 days education; programme stated 9 CPD credits
Alleged hospitality elements5-star venue; programme emphasis on social aspects; golf and gala dinner listed after scientific close
Applicable Code year2012
Complaint received26 November 2012
Case completed12 February 2013
AppealNo appeal
Breach findingsBreach Clause 9.1; No breach Clauses 2 and 19.1
SanctionsUndertaking received

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • An anonymous, non-contactable group of NHS health professionals complained about pharmaceutical company support for the Irish Society of Urology (ISU) annual meeting held in Belfast (Northern Ireland) in September 2012.
  • The programme and venue created a strong hospitality-led impression: a 5-star venue (Culloden Estate and Spa), prominent photos of luxury/attractions, and a welcome message emphasising the “social aspect” and a gala dinner at Stormont.
  • The programme showed scientific sessions over ~1.5 days (9 CPD credits), with golf and a gala dinner listed after the scientific meeting closed.
  • Allergan did not exhibit; it provided an educational grant of €1,850 intended for venue hire and AV costs, with requested wording stating Allergan had no involvement in logistics, design or content.
  • The back page of the programme listed multiple companies thanked for “support” without clearly stating what each company supported, creating ambiguity about whether companies supported the social elements.
  • The Panel noted the ABPI Code applied because the meeting was held in Northern Ireland, and UK companies are responsible for overseas affiliates’ activities when carried out in the UK or relating to UK health professionals.
⚖️

Outcome

  • Breach: Clause 9.1.
  • No breach: Clause 19.1.
  • No breach: Clause 2.
  • The Panel’s key concern for Allergan was the overall impression created by the programme and sponsorship acknowledgements, rather than evidence that Allergan funded golf/gala dinner or sponsored delegates.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training